Nonetheless, an analysis of prostate cancer patients and metastatic breast cancer patients did not observe any difference among varying daily doses [44,72], suggesting that the relationship between CD8+ T cell responses and the daily dose should be investigated in detail. This evidence concerns the gene CD8A and prostate cancer.